# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Evel Knievel (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB001-SYN-TD
- Date: 1996-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Dale Rasmussen, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

End of 12 weeks of hepatitis C treatment. **S**

## History of present illness

Mr. Knievel finished sofosbuvir-velpatasvir yesterday without missing a dose. He has had no alcohol since the day treatment started. He takes carvedilol 12.5 mg daily without dizziness. His glucose sensor has shown no readings below 70 mg/dL. The bone density scan ten weeks ago showed osteoporosis at the hip. He has had no falls since starting physical therapy, walks 20 minutes on flat ground and swims twice a week; pain is about 4 of 10. He has not yet had his diabetic eye examination because the appointment was not booked after the referral. He saw his dentist last week. He has had no muscle aches, abdominal swelling, black stools, confusion or yellow eyes. He has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | 12 weeks of sofosbuvir-velpatasvir completed; no missed doses |
| Alcohol | None for 12 weeks |
| Bone density | Femoral neck T-score -2.6; lumbar spine -1.9 |
| Glucose sensor | Glucose management indicator 6.9%; no lows |
| Eye examination | Not yet done |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | More energy; weight down 1.6 kg |
| Gastrointestinal | Negative | No abdominal swelling, black stools or nausea |
| Musculoskeletal | Positive | Hip and knee pain, 4 of 10; no muscle aches |
| Endocrine | Negative | No low glucose readings |
| Neurological | Negative | No confusion or tremor |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth up to twice a day as needed for pain, no more than 2 g a day **S**
- Diclofenac sodium 1% topical gel, 4 g to the knees up to four times a day **S**
- Carvedilol 12.5 mg oral tablet, one tablet daily **S**
- Atorvastatin 20 mg oral tablet, one tablet daily **S**
- Cholecalciferol (vitamin D3) 50 mcg (1970 units) oral capsule, one capsule daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/72 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 83.2 kg; BMI 26.3 kg/m². All vital signs are synthetic.

Hemoglobin: 14.2 g/dL; White cell count: 5 10*3/uL; Platelets: 129 10*3/uL (low); Creatinine: 0.89 mg/dL; eGFR (CKD-EPI 1991): 100 mL/min/1.73 m²; Glucose (fasting): 118 mg/dL (high); ALT: 24 U/L; AST: 29 U/L; Total bilirubin: 0.8 mg/dL; Albumin: 3.9 g/dL; Calcium: 9.3 mg/dL; HCV RNA (quantitative): 0 [IU]/mL; Hemoglobin A1c: 6.4% (high); Glucose management indicator (14-day CGM): 6.9%; 25-hydroxyvitamin D: 34 ng/mL; Parathyroid hormone (intact): 48 pg/mL; Testosterone (morning): 455 ng/dL; AUDIT-C: 0; PHQ-9: 4; Pain (0 to 10): 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.9 g/dL at baseline, 14.2 g/dL at this visit **S**
- White cell count: 4.6 10*3/uL at baseline, 5 10*3/uL at this visit **S**
- Platelets: 118 10*3/uL (low) at baseline, 129 10*3/uL (low) at this visit **S**
- Creatinine: 0.92 mg/dL at baseline, 0.89 mg/dL at this visit **S**
- eGFR (CKD-EPI 1991): 97 mL/min/1.73 m² at baseline, 100 mL/min/1.73 m² at this visit **S**
- Glucose (fasting): 162 mg/dL (high) at baseline, 118 mg/dL (high) at this visit **S**
- ALT: 88 U/L (high) at baseline, 24 U/L at this visit **S**
- AST: 96 U/L (high) at baseline, 29 U/L at this visit **S**
- Total bilirubin: 1.1 mg/dL at baseline, 0.8 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 3.9 g/dL at this visit **S**
- Hemoglobin A1c: 7.4% (high) at baseline, 6.4% (high) at this visit **S**
- AUDIT-C: 7 at baseline, 0 at this visit **S**
- Pain (0 to 10): 7 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 83.2 kg; blood pressure 118/72, pulse 62 |
| Skin | Spider angiomas fewer; no jaundice |
| Abdomen | Spleen tip palpable; no ascites |
| Mouth | Teeth in good repair |
| Neurological | No asterixis; gait steady with a cane |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic hepatitis C, genotype 1a, end of treatment** (B18.2). Treatment completed with full adherence. HCV RNA is not detected at the end of treatment and ALT 24 and AST 29 U/L are normal; cure is confirmed only by a test 12 or more weeks from now. **S**
   - HCV RNA and liver tests 12 or more weeks after the last dose, with the six-month ultrasound.
2. **Osteoporosis** (M81.8). Femoral neck T-score -2.6 with a 10-year hip fracture risk of 4.1% in a man with cirrhosis, prior heavy alcohol use and dozens of old fractures: treatment is indicated. Secondary causes are addressed: vitamin D now 34 ng/mL, calcium 9.3 mg/dL, parathyroid hormone 48 pg/mL and testosterone 455 ng/dL are normal. An oral bisphosphonate can irritate the esophagus, which is a concern with portal hypertension and possible varices, so a yearly zoledronic acid infusion is preferred. His dental check is done. **S**
   - Zoledronic acid 5 mg intravenously in two weeks.
   - Calcium from food about 1000 mg a day; continue vitamin D3.
   - Bone density again in two years.
3. **Type 2 diabetes in cirrhosis** (E11.65). A1c 6.4% but a glucose management indicator of 6.9%: the A1c reads lower than the true average, as it can in cirrhosis, so the sensor guides treatment. No hypoglycemia on metformin as the virus cleared. **S**
   - Continue metformin and the sensor.
   - Eye examination booked today for next month.
4. **Clinically significant portal hypertension** (K76.6). Pulse 62 and blood pressure 118/72 on carvedilol 12.5 mg. **S**
   - Continue carvedilol.
5. **Vitamin D deficiency** (E55.9). Vitamin D 34 ng/mL after replacement; resolved. **S**
   - Continue vitamin D3 1970 units daily.
6. **Chronic pain from old fractures** (G89.29). 4 of 10; walking 20 minutes; no NSAIDs or opioids. **S**
   - Continue aquatic therapy and the home program.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | HCV RNA at the end of treatment | Optional at the end of treatment | Completed today | Not detected |
| Laboratory | Hepatic function panel, blood count and kidney function | At the end of treatment in cirrhosis, as needed | Completed today | ALT 24, AST 29 U/L, bilirubin 0.8 mg/dL, albumin 3.9 g/dL; platelets 129, hemoglobin 14.2 g/dL, white cells 5.0; creatinine 0.89 mg/dL, eGFR 100 |
| Medication safety | Adherence and side effects | During treatment | Completed today | No missed doses; no side effects; no muscle aches on atorvastatin |
| Laboratory | Glucose control in cirrhosis: A1c with sensor data | Every three months when therapy changes | Completed today | A1c 6.4%; glucose management indicator 6.9%; fasting glucose 118 mg/dL; no hypoglycemia |
| Referral | Diabetic eye examination | Yearly | Deferred | A deviation: referred two visits ago but never booked, because the referral was sent without an appointment request. No harm is known; he has no visual symptoms. Corrective action: booked today for next month, with a reminder to confirm the result |
| Imaging | Bone density (DXA) | Men at risk | Up to date | Ten weeks ago: femoral neck T-score -2.6, lumbar spine -1.9; FRAX hip fracture risk 4.1% |
| Laboratory | Secondary causes of osteoporosis and calcium before zoledronic acid | Before starting treatment | Completed today | Vitamin D 34 ng/mL, calcium 9.3 mg/dL, parathyroid hormone 48 pg/mL, testosterone 455 ng/dL |
| Medication safety | Dental review before a bisphosphonate | Before the first dose | Up to date | Seen by his dentist last week |
| Medication safety | Carvedilol: blood pressure and heart rate | Each visit | Completed today | 118/72, pulse 62 |
| Imaging | Liver ultrasound for cancer surveillance | Every six months in cirrhosis | Due | Due in July, six months after the baseline scan |
| Examination | Signs of decompensation (ascites, encephalopathy, jaundice, bleeding) | Each visit in cirrhosis | Completed today | None |
| Self-management | Falls and fracture risk | Each visit | Completed today | No falls since physical therapy; cane outdoors |
| Survey | Alcohol use (AUDIT-C) | Each visit in liver disease | Completed today | AUDIT-C 0 |
| Survey | Pain score and function | Each visit | Completed today | 4 of 10 |
| Survey | Depression screen (PHQ-9) | At diagnosis and when treatment changes | Completed today | PHQ-9 4 |

## Goal progress

- Hepatitis C confirmed or excluded and liver disease staged within three weeks. Outcome by 1996-01-26: Chronic hepatitis C, genotype 1a, with compensated cirrhosis staged at two weeks. **S**
- Cure of hepatitis C: HCV RNA not detected 12 or more weeks after treatment. In progress; target 1996-08-17. **S**
- No decompensation (ascites, variceal bleeding, encephalopathy or jaundice); Child-Pugh A and MELD-Na below 15. In progress; target 1996-08-17. **S**
- No alcohol. In progress; target 1996-08-17. **S**
- Pain 4 of 10 or less, walking 30 minutes, with no oral NSAIDs or opioids. In progress; target 1996-08-17. **S**
- Glucose management indicator below 7% without hypoglycemia. In progress; target 1996-08-17. **S**
- Vitamin D replete and osteoporosis treatment started; no falls with injury. In progress; target 1996-08-17. **S**

## Guideline basis

- AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Simplified HCV treatment algorithm for treatment-naive adults with compensated cirrhosis (2023), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- AASLD-IDSA HCV Guidance: Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy (2026), American Association for the Study of Liver Diseases and Infectious Diseases Society of America
- EPCLUSA (sofosbuvir and velpatasvir) tablets, prescribing information (2025), U.S. National Library of Medicine, DailyMed (Gilead Sciences label)
- Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 2023;78(6):1922-1965 (PMID 37199193) (2023), American Association for the Study of Liver Diseases
- de Franchis R, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol 2022;76(4):959-974 (PMID 35120736) (2022), Baveno VII Faculty (Journal of Hepatology)
- Kaplan DE, et al. AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology 2024;79(5):1180-1211 (PMID 37870298) (2024), American Association for the Study of Liver Diseases
- Biggins SW, et al. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the AASLD. Hepatology 2021;74(2):1014-1048 (PMID 33942342) (2021), American Association for the Study of Liver Diseases
- Crabb DW, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the AASLD. Hepatology 2020;71(1):306-333 (PMID 31314133) (2019), American Association for the Study of Liver Diseases
- Rakoski M, Goyal P, Spencer-Safier M, et al. Pain management in patients with cirrhosis. Clin Liver Dis (Hoboken) 2018;11(6):135-140 (PMID 30992804) (2018), American Association for the Study of Liver Diseases (Clinical Liver Disease)
- Dowell D, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022;71(3):1-95 (PMID 36327391) (2022), Centers for Disease Control and Prevention
- American Diabetes Association. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S61-S88 (PMID 41358897) (2026), American Diabetes Association
- American Diabetes Association. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care 2026;49(Suppl 1):S132-S149 (PMID 41358894) (2026), American Diabetes Association
- Watts NB, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97(6):1802-1822 (PMID 22675062) (2012), Endocrine Society
- Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (2018), U.S. Preventive Services Task Force
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, osteoporosis and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Zoledronic acid infusion in two weeks. Eye examination next month. Liver ultrasound in July. Review with HCV RNA, liver tests and alpha-fetoprotein 12 or more weeks after the last dose. **S**
- Next scheduled visit 1996-08-17: cure confirmed (SVR12): six-month liver cancer surveillance, cirrhosis care after cure, and transplant criteria reviewed. **S**
